Publicaciones en colaboración con investigadores/as de University of Verona (11)

2021

  1. Antimicrobial resistance research in a post-pandemic world: Insights on antimicrobial resistance research in the COVID-19 pandemic

    Journal of Global Antimicrobial Resistance, Vol. 25, pp. 5-7

  2. Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance

    Transactions of the Royal Society of Tropical Medicine and Hygiene, Vol. 115, Núm. 10, pp. 1122-1129

2020

  1. Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections: are the MICs useful for clinicians?

    Clinical Microbiology and Infection, Vol. 26, Núm. 8, pp. 1024-1033

2017

  1. Etestw versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: Results from PREMIUM, a European multicentre study

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 2, pp. 431-436

2012

  1. Emergence of antibiotic resistance: Need for a new paradigm

    Clinical Microbiology and Infection, Vol. 18, Núm. 7, pp. 615-616

2010

  1. A European survey of antibiotic management of methicillin-resistant staphylococcus aureus infection: Current clinical opinion and practice

    Clinical Microbiology and Infection, Vol. 16, Núm. SUPPL. 1, pp. 3-30

  2. Acquired carbapenemases in Gram-negative bacterial pathogens: Detection and surveillance issues

    Clinical Microbiology and Infection, Vol. 16, Núm. 2, pp. 112-122

  3. Public health microbiology, a challenge for Europe

    Clinical Microbiology and Infection, Vol. 16, Núm. 2, pp. 123-125

2007

  1. Learning from mistakes: Taq polymerase contaminated with β-lactamase sequences results in false emergence of Streptococcus pneumoniae containing TEM [1]

    Journal of Antimicrobial Chemotherapy

  2. Metallo-β-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues

    International Journal of Antimicrobial Agents

2003

  1. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults

    Journal of Antimicrobial Chemotherapy, Vol. 52, Núm. 5, pp. 826-836